FeesSafety
Pluang+

Travere Therapeutics' shares triple after two FDA approvals boost revenue growth.

Analyst Insights
16 Nov 2026, 15:25 WIB
Seeking Alpha
View Source
Bullish
Travere Therapeutics' shares triple after two FDA approvals boost revenue growth.

Travere Therapeutics has secured two FDA approvals for its drug FILSPARI, leading to significant revenue growth and a near tripling of its stock price since August 2025. This strong momentum reflects investor confidence in the company's new revenue streams. However, questions remain about whether Travere can sustain this rapid growth given current valuations and future prospects. Investors should watch for how the company manages growth beyond these initial successes.

Travere Therapeutics shares have shown resilience with a slight gain of 0.10% on Pluang, trading at USD 50.70 as of Nov 16, 2026 20:42 WIB. The stock remains well below its 52-week high of USD 67.52, indicating room for movement amid ongoing growth discussions.

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App